Evotec AG shares tumbled approximately 30% in early European trading on Tuesday, sinking to their lowest level in roughly ten years.
The sell-off was triggered by the company's issuance of a profit warning, signaling that financial results are expected to fall short of market expectations.
The dramatic drop reflects a loss of confidence among investors regarding the Hamburg-based biotech firm's ability to deliver on its growth narrative.
With the stock hitting a decade low, the move suggests that the market is rapidly repricing the risk associated with Evotec's current operational and financial trajectory.
This development comes at a time when biotech equities are facing heightened scrutiny over profitability and cash burn rates.
The profit warning indicates potential challenges in Evotec's core business segments, prompting a reassessment of the company's valuation by equity analysts and portfolio managers.